Last updated: July 26, 2026
What is the latest clinical trials pipeline for amphetamine sulfate?
No complete, up-to-date, source-grounded clinical-trials dataset is available in the provided information to compile an accurate “latest” status by trial phase, sponsor, site, or readout date. Without that dataset, a trials update would risk mixing current and stale listings, and would not support litigation-grade precision.
Which trial designs dominate amphetamine sulfate studies?
No trial-specific information is available here to map designs (randomized, crossover, bioequivalence, dose-ranging, pediatric extrapolation), endpoints (ADHD symptom scales, functioning outcomes, appetite/weight, cardiovascular parameters), or regulatory endpoints (BE/bridging vs efficacy).
Are new formulations driving new studies?
No formulation-specific or developer-specific pipeline detail is available here to confirm sustained-release, prodrug, new salt form, or alternative delivery routes for amphetamine sulfate.
How big is the amphetamine sulfate market today and what segment drives demand?
No market sizing inputs, geography splits, pack pricing, share breakdown across strengths, or payer mix are provided here. A credible market analysis requires at least one anchored dataset (IQVIA, Symphony Health, SSR Health, company filings, NDC-level retail and/or channel data), which is not included.
Which indication dominates: ADHD vs off-label uses
No indication split, utilization-weighted prescribing data, or claims-based breakdown is available here to attribute demand to ADHD versus off-label or comorbidity-related use.
What channel mix matters most (retail vs institutional vs specialty)?
No distribution or channel data is available here to quantify retail vs institutional pull-through for amphetamine sulfate.
When does amphetamine sulfate face exclusivity loss and generic entry risk?
No Orange Book listing data, patent-by-patent expiration dates, pediatric exclusivity terms, or 180-day exclusivity status is included here. Without those, any exclusivity and generic-entry assessment would be incomplete.
What patents typically cover amphetamine sulfate products?
No product-specific patent estate is provided here to enumerate active ingredient, formulation, polymorph, process, or method-of-use protection.
How do Paragraph IV filings affect future pricing?
No Orange Book Paragraph IV history or settlement terms are included here to model entry timing, share capture, or erosion.
What is the FDA regulatory status of amphetamine sulfate products (Orange Book, approvals, labels)?
No product-level FDA data is provided here to confirm approval type (NDA vs ANDA), reference product, label version, strengths, dosage forms, pediatric labeling status, or REMS (if any).
Which FDA review pathway is used for generics of amphetamine sulfate?
No ANDA/505(j) or NDA history is included here to characterize typical regulatory posture.
How do shortages and supply constraints affect access and revenue?
No supply or shortage indicators are provided here to map QRF/controlled substance scheduling impacts, distributor inventory cycles, or backorder durations.
How strong is the patent estate for amphetamine sulfate generics and what litigation exists?
No litigation docket, PTAB history, settlement dates, or asserted patents are provided. A patent-strength assessment requires actual patent numbers, claims, jurisdiction, and case posture.
What companies are challenging amphetamine sulfate products?
No ANDA filers, applicant names, or challenger identities are included.
What settlement terms determine launch dates or “authorized generic” timing?
No settlement agreement terms are provided.
What formulation patents cover amphetamine sulfate and do they change the competitive landscape?
No formulation-specific assets are included in the provided information. Without patent identifiers tied to specific dosage forms or release profiles, formulation protection cannot be mapped.
Immediate-release vs extended-release: what is protected?
No product-level mapping exists here to connect dosage form to patent claims.
Manufacturing-process barriers: are there any process patents?
No process patent information is available here.
How does amphetamine sulfate compare with lisdexamfetamine, mixed amphetamine salts, and methylphenidate on market trajectory?
No head-to-head market data, relative pricing, share shifts, switching rates, or cohort-level persistence is provided here. A comparison requires consistent market-series data and payer/segment splits.
Switching dynamics: do patients move from amphetamine sulfate to lisdexamfetamine?
No switching or persistence data is available here.
Managed care controls: formulary access and step edits
No formulary and utilization-control information is included here.
Revenue projection for amphetamine sulfate: base, bull, and bear cases (2026-2036)
No data inputs are provided to anchor projections: current unit volumes, average wholesale price or net price, reimbursement rates, generic erosion assumptions, or entry timing. Without those, any numerical projection would be fabricated.
Projection drivers used in modeling (what must be sourced)
No source-grounded inputs exist here to populate:
- Current market size and growth rate by geography and dose form
- Generic penetration trajectory and 180-day exclusivity events
- Net price erosion curve post-first ANDA entry
- Estimated controlled-substance supply constraints and shortage adjustments
- Indication mix and pediatric prescribing trends
- Competitive dynamics versus lisdexamfetamine and methylphenidate
Key Takeaways
- A source-grounded clinical-trials update, exclusivity/generic-entry timeline, and revenue projection for amphetamine sulfate cannot be produced from the information provided.
- Market analysis requires anchored datasets (claims, NDC sales, pricing, market share by payer and channel).
- Patent and regulatory assessment requires Orange Book, patent-by-patent expirations, ANDA history, litigation, and any settlements.
FAQs
- What clinical trial registry entries exist for amphetamine sulfate in ADHD and related indications?
- Which amphetamine sulfate NDCs have the most near-term generic entry risk?
- How many Paragraph IV certifications have been filed for amphetamine sulfate products?
- What is the typical net pricing and erosion pattern for generic amphetamine sulfate after first ANDA launch?
- How do formulary controls in Medicaid and commercial plans affect amphetamine sulfate utilization?
References
No sources were provided in the prompt, and no cited materials are available to compile an APA reference list.
